재발성 외음질 칸디다증(RVVC) : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Recurrent Vulvovaginal Candidiasis (RVVC) Emerging Therapy and TPP Insights

Thelansis's "Recurrent Vulvovaginal Candidiasis (RVVC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Recurrent Vulvovaginal Candidiasis (RVVC) Overview

Recurrent vulvovaginal candidiasis (RVVC) is defined as four or more symptomatic infections within twelve months, primarily driven by Candida albicans. However, the non-albicans strain Nakaseomyces glabrata (formerly Candida glabrata) is increasingly implicated, carrying a highly azole-resistant susceptibility profile. Pathophysiology involves local cell-mediated immune dysregulation, microbiota imbalances, and fungal biofilm formation. Predisposing factors include uncontrolled diabetes, elevated estrogen, and antibiotic use. Symptoms feature intense vulvovaginal pruritus, burning, and thick, curd-like discharge. Diagnosis mandates vaginal pH testing, microscopy, and fungal cultures with explicit species identification. Conventional management uses fluconazole induction followed by six months of weekly maintenance suppression. For females of non-reproductive potential, the highly selective oral fungal CYP51 inhibitor oteseconazole represents a landmark approved advance that avoids human CYP drug-drug interactions. For patients of childbearing potential or those facing azole-resistant N. glabrata strains, the oral triterpenoid glucan synthase inhibitor ibrexafungerp provides a vital, non-azole therapeutic mechanism. Prognosis relies on managing underlying risk factors and tailoring multi-month suppressive regimens.

Key Highlights

• In Germany, the diagnosed RVVC prevalence pool is projected to increase from approximately 622,099 to 715,204 by 2035, reflecting a growing disease burden.
• Increasing prevalence of non-albicans Candida species is contributing to greater antifungal resistance and treatment complexity.
• Persistent recurrence and relapse continue to significantly impact patient quality of life and healthcare utilization.
• Novel antifungal agents are expanding treatment options for patients with recurrent or resistant disease.
• Growing awareness of women's health conditions and improved diagnostic testing are supporting increased patient identification and treatment uptake.

Market Overview

• The France RVVC market is projected to grow from approximately $24 MN to $60 MN by 2035, reflecting notable market expansion.
• Market growth is supported by:
• Increasing adoption of novel antifungal therapies for recurrent disease management
• Rising awareness and diagnosis of resistant and recurrent infections
• Market value growth is driven by long-term suppressive treatment strategies and increasing demand for durable therapeutic options.
• Future market growth will depend on next-generation antifungal agents, resistance-targeted therapies, and preventive therapeutic approaches including vaccines and immunotherapies.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• LimmaTech Biologics AG
• Mycovia Pharmaceuticals Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)